Sensibilité in vitro de souches de Streptococcus pyogenes récemment isolées d'angines communautaires

Cohen, Robert; Frémaux, A.; Gouvello, A. de; Deforche, V.; Lévy, C.; Wadbled, D.; Rocque, F. De La; Varon, E.; Geslin, P.

doi:10.1016/s0399-077x(96)80032-1

Cited by 9 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The level of resistance of GABHS to macrolides found in this study before treatment was comparable with those found in previous studies in France [22,23].…”

Section: Methodssupporting

confidence: 91%

Azithromycin versus penicillin in acute group A streptococcal tonsillopharyngitis

Brook¹

2003

Curr Infect Dis Rep

View full text Add to dashboard Cite

“…The level of resistance of GABHS to macrolides found in this study before treatment was comparable with those found in previous studies in France [22,23].…”

Section: Methodssupporting

confidence: 91%

Azithromycin versus penicillin in acute group A streptococcal tonsillopharyngitis

Brook¹

2003

Curr Infect Dis Rep

View full text Add to dashboard Cite

“…Erythromycin resistance due to an efflux mechanism (M phenotype), encoded by mef genes, has recently been described (6,45). While the prevalence of the S. pyogenes resistance to macrolides has been reported worldwide, very few recent data deal with the French situation (1,8). The aims of this study were to assess the macrolide sensitivity of recent throat isolates of S. pyogenes collected from French children, to determine the genetic mechanisms of resistance, and to explore clonality by means of serotyping and molecular methods.…”

mentioning

confidence: 99%

“…However, for patients sensitive to ␤-lactam antibiotics, and when these drugs fail, macrolides are often the recommended substitute. Penicillin resistance has not yet been described in S. pyogenes, but resistance to erythromycin and related antibiotics has been widely reported (2,3,5,8,10,11,17,20,29,33,43,46). The mechanism of acquired resistance to erythromycin involves a target site modification mediated by a methylase which modifies the 50S ribosomal subunit, leading to the MLS B resistance phenotype encoded by erm genes (25,36,47).…”

mentioning

confidence: 99%

Resistance to Macrolides in Streptococcus pyogenes in France in Pediatric Patients

Bingen

Fitoussi

Doit

et al. 2000

Antimicrob Agents Chemother

105

View full text Add to dashboard Cite

A total of 1,500 recent throat isolates of Streptococcus pyogenes collected between 1996 and 1999 from children throughout France were tested for their susceptibility to erythromycin, azithromycin, josamycin, clindamycin, and streptogramin B. The erythromycin-resistant isolates were further studied for their genetic mechanism of resistance, by means of PCR. The clonality of these strains was also investigated by means of serotyping and ribotyping. In all, 6.2% of the strains were erythromycin resistant, and 3.4 and 2.8% expressed the constitutive MLS B and M resistance phenotypes and harbored the ermB and mefA genes, respectively; ermTR was recovered from one isolate which also harbored the ermB gene. Ten serotypes and 8 ribotypes were identified, but we identified 17 strains by combining serotyping with ribotyping. Among the eight ribotypes, the mefA gene was recovered from six clusters, one being predominant, while the ermB gene was recovered from four clusters, of which two were predominant.Penicillin is the drug of choice for the treatment of Streptococcus pyogenes infection. However, for patients sensitive to ␤-lactam antibiotics, and when these drugs fail, macrolides are often the recommended substitute. Penicillin resistance has not yet been described in S. pyogenes, but resistance to erythromycin and related antibiotics has been widely reported (2,3,5,8,10,11,17,20,29,33,43,46). The mechanism of acquired resistance to erythromycin involves a target site modification mediated by a methylase which modifies the 50S ribosomal subunit, leading to the MLS B resistance phenotype encoded by erm genes (25,36,47). Erythromycin resistance due to an efflux mechanism (M phenotype), encoded by mef genes, has recently been described (6,45). While the prevalence of the S. pyogenes resistance to macrolides has been reported worldwide, very few recent data deal with the French situation (1,8). The aims of this study were to assess the macrolide sensitivity of recent throat isolates of S. pyogenes collected from French children, to determine the genetic mechanisms of resistance, and to explore clonality by means of serotyping and molecular methods. MATERIALS AND METHODSBacterial isolates. A total of 1,500 consecutive S. pyogenes isolates were collected between 1996 and 1999 throughout France. They were isolated by swabbing the throats of children, 4 to 17 years old (mean age, 11 years), with pharyngitis. The isolates were identified as S. pyogenes by colony morphology, beta-hemolysis on blood agar, and a commercial agglutination technique (Murex Diagnostics UK).Susceptibility testing. The procedures for susceptibility testing were those recommended by the National Committee for Clinical Laboratory Standards (NCCLS) (30).(i) Detection of erythromycin resistance and determination of resistance phenotypes. Erythromycin-resistant strains were initially identified by the disk diffusion method on Mueller-Hinton agar supplemented with 5% defibrinated horse blood (Diagnostic Pasteur, Marnes la Coquette, France) using 15-g erythrom...

show abstract

Traitement des infections respiratoires hautes bactériennes

par¹,

Boyer-Grand²,

par³

et al. 2008

Pharmacie Clinique Et Thérapeutique

View full text Add to dashboard Cite

Sensibilité in vitro de souches de Streptococcus pyogenes récemment isolées d'angines communautaires

Cited by 9 publications

References 9 publications

Azithromycin versus penicillin in acute group A streptococcal tonsillopharyngitis

Azithromycin versus penicillin in acute group A streptococcal tonsillopharyngitis

Resistance to Macrolides in Streptococcus pyogenes in France in Pediatric Patients

Traitement des infections respiratoires hautes bactériennes

Contact Info

Product

Resources

About